Does the media prefer AXSM or JAZZ?

In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Axsome Therapeutics. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 9 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.67 beat Jazz Pharmaceuticals' score of 0.50 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ZTS or JAZZ?

In the previous week, Zoetis had 25 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 46 mentions for Zoetis and 21 mentions for Jazz Pharmaceuticals. Zoetis' average media sentiment score of 0.96 beat Jazz Pharmaceuticals' score of 0.50 indicating that Zoetis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zoetis 25 Very Positive mention(s) 2 Positive mention(s) 18 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RPRX or JAZZ?

In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Royalty Pharma. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.02 beat Jazz Pharmaceuticals' score of 0.50 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 5 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CORT or JAZZ?

In the previous week, Corcept Therapeutics had 11 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 32 mentions for Corcept Therapeutics and 21 mentions for Jazz Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.78 beat Jazz Pharmaceuticals' score of 0.50 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 9 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SUPN or JAZZ?

In the previous week, Jazz Pharmaceuticals had 17 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.54 beat Jazz Pharmaceuticals' score of 0.50 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jazz Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Jazz Pharmaceuticals (JAZZ) Competitors

$236.49 +1.11 (+0.47%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$236.45 -0.04 (-0.02%)

As of 05/29/2026 07:11 PM Eastern

Compare

JAZZ vs. AXSM, ZTS, RPRX, CORT, and SUPN

Should you buy Jazz Pharmaceuticals stock or one of its competitors? MarketBeat compares Jazz Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jazz Pharmaceuticals include Axsome Therapeutics (AXSM), Zoetis (ZTS), Royalty Pharma (RPRX), Corcept Therapeutics (CORT), and Supernus Pharmaceuticals (SUPN). These companies are all part of the "medical" sector.

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Axsome Therapeutics. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 9 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.67 beat Jazz Pharmaceuticals' score of 0.50 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Axsome Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.90	-$183.17M	-$3.73	N/A
Jazz Pharmaceuticals	$4.27B	3.48	-$356.15M	-$0.02	N/A

Jazz Pharmaceuticals has a net margin of 0.66% compared to Axsome Therapeutics' net margin of -26.59%. Jazz Pharmaceuticals' return on equity of 14.56% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market.

Axsome Therapeutics currently has a consensus price target of $251.26, suggesting a potential upside of 7.16%. Jazz Pharmaceuticals has a consensus price target of $242.65, suggesting a potential upside of 2.60%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.90
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Axsome Therapeutics beats Jazz Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Zoetis?

Zoetis (NYSE:ZTS) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, risk, media sentiment, profitability and earnings.

Zoetis presently has a consensus target price of $133.92, suggesting a potential upside of 72.11%. Jazz Pharmaceuticals has a consensus target price of $242.65, suggesting a potential upside of 2.60%. Given Zoetis' higher possible upside, research analysts plainly believe Zoetis is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zoetis	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Zoetis has a beta of 0.75, indicating that its share price is 25% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market.

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Zoetis had 25 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 46 mentions for Zoetis and 21 mentions for Jazz Pharmaceuticals. Zoetis' average media sentiment score of 0.96 beat Jazz Pharmaceuticals' score of 0.50 indicating that Zoetis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zoetis	25 Very Positive mention(s)	2 Positive mention(s)	18 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Zoetis has a net margin of 27.80% compared to Jazz Pharmaceuticals' net margin of 0.66%. Zoetis' return on equity of 66.85% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zoetis	27.80%	66.85%	18.79%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Zoetis has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zoetis	$9.47B	3.45	$2.67B	$6.03	12.90
Jazz Pharmaceuticals	$4.27B	3.48	-$356.15M	-$0.02	N/A

Summary

Zoetis beats Jazz Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Royalty Pharma has a net margin of 33.88% compared to Jazz Pharmaceuticals' net margin of 0.66%. Royalty Pharma's return on equity of 29.25% beat Jazz Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	33.88%	29.25%	14.71%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Royalty Pharma has a beta of 0.43, suggesting that its stock price is 57% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Royalty Pharma presently has a consensus price target of $53.71, indicating a potential downside of 3.67%. Jazz Pharmaceuticals has a consensus price target of $242.65, indicating a potential upside of 2.60%. Given Jazz Pharmaceuticals' higher possible upside, analysts plainly believe Jazz Pharmaceuticals is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

Royalty Pharma has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.50	$770.95M	$1.47	37.93
Jazz Pharmaceuticals	$4.27B	3.48	-$356.15M	-$0.02	N/A

In the previous week, Jazz Pharmaceuticals had 12 more articles in the media than Royalty Pharma. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.02 beat Jazz Pharmaceuticals' score of 0.50 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	5 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 18.8% of Royalty Pharma shares are owned by company insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Royalty Pharma beats Jazz Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Corcept Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	9.80	$99.65M	$0.35	198.54
Jazz Pharmaceuticals	$4.27B	3.48	-$356.15M	-$0.02	N/A

Corcept Therapeutics has a beta of 0.5, suggesting that its share price is 50% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the broader market.

Corcept Therapeutics currently has a consensus target price of $88.83, indicating a potential upside of 27.84%. Jazz Pharmaceuticals has a consensus target price of $242.65, indicating a potential upside of 2.60%. Given Corcept Therapeutics' higher probable upside, research analysts clearly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Corcept Therapeutics had 11 more articles in the media than Jazz Pharmaceuticals. MarketBeat recorded 32 mentions for Corcept Therapeutics and 21 mentions for Jazz Pharmaceuticals. Corcept Therapeutics' average media sentiment score of 0.78 beat Jazz Pharmaceuticals' score of 0.50 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	9 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

93.6% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 20.7% of Corcept Therapeutics shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Corcept Therapeutics has a net margin of 6.14% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Jazz Pharmaceuticals had 17 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 21 mentions for Jazz Pharmaceuticals and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.54 beat Jazz Pharmaceuticals' score of 0.50 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Supernus Pharmaceuticals has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.73	-$38.55M	-$0.51	N/A
Jazz Pharmaceuticals	$4.27B	3.48	-$356.15M	-$0.02	N/A

Supernus Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the broader market.

Jazz Pharmaceuticals has a net margin of 0.66% compared to Supernus Pharmaceuticals' net margin of -3.74%. Jazz Pharmaceuticals' return on equity of 14.56% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

Supernus Pharmaceuticals currently has a consensus price target of $62.17, indicating a potential upside of 34.62%. Jazz Pharmaceuticals has a consensus price target of $242.65, indicating a potential upside of 2.60%. Given Supernus Pharmaceuticals' higher possible upside, research analysts plainly believe Supernus Pharmaceuticals is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Jazz Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.89

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Jazz Pharmaceuticals beats Supernus Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Jazz Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JAZZ vs. The Competition

Export

Metric	Jazz Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.84B	$3.41B	$6.58B	$12.59B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	-11,818.59	18.88	21.59	26.25
Price / Sales	3.48	334.85	561.77	114.93
Price / Cash	14.54	54.19	27.44	37.60
Price / Book	3.33	6.93	10.04	6.86
Net Income	-$356.15M	$24.20M	$3.56B	$337.26M
7 Day Performance	-1.39%	4.11%	2.85%	3.58%
1 Month Performance	16.49%	6.66%	4.59%	5.71%
1 Year Performance	118.41%	66.00%	37.62%	39.70%

Jazz Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JAZZ Jazz Pharmaceuticals	2.6182 of 5 stars	$236.49 +0.5%	$242.65 +2.6%	+118.4%	$14.84B	$4.27B	N/A	2,890	Trending News Analyst Upgrade Insider Trade Analyst Revision
AXSM Axsome Therapeutics	2.4051 of 5 stars	$235.97 flat	$251.26 +6.5%	+123.5%	$12.14B	$638.50M	N/A	380
ZTS Zoetis	4.9993 of 5 stars	$81.26 -0.1%	$133.92 +64.8%	-53.9%	$34.09B	$9.47B	13.48	14,500	Trending News Analyst Forecast
RPRX Royalty Pharma	4.5722 of 5 stars	$54.50 flat	$53.71 -1.4%	+68.7%	$31.38B	$2.38B	37.08	80	Positive News Insider Trade
CORT Corcept Therapeutics	4.614 of 5 stars	$60.22 flat	$70.83 +17.6%	-11.0%	$6.46B	$761.41M	172.06	300	Trending News Analyst Forecast Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JAZZ) was last updated on 5/31/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, ZTS, RPRX, CORT, and SUPN

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Summary

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Summary

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jazz Pharmaceuticals (JAZZ) Competitors

JAZZ vs. AXSM, ZTS, RPRX, CORT, and SUPN

How does Jazz Pharmaceuticals compare to Axsome Therapeutics?

Does the media prefer AXSM or JAZZ?

Which has preferable valuation & earnings, AXSM or JAZZ?

Is AXSM or JAZZ more profitable?

Do institutionals and insiders hold more shares of AXSM or JAZZ?

Which has more volatility and risk, AXSM or JAZZ?

Do analysts prefer AXSM or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Zoetis?

Do analysts prefer ZTS or JAZZ?

Which has more volatility & risk, ZTS or JAZZ?

Do insiders and institutionals hold more shares of ZTS or JAZZ?

Does the media favor ZTS or JAZZ?

Is ZTS or JAZZ more profitable?

Which has stronger earnings and valuation, ZTS or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Royalty Pharma?

Is RPRX or JAZZ more profitable?

Which has more risk and volatility, RPRX or JAZZ?

Do analysts prefer RPRX or JAZZ?

Which has preferable earnings & valuation, RPRX or JAZZ?

Does the media refer more to RPRX or JAZZ?

Do insiders & institutionals hold more shares of RPRX or JAZZ?

Summary

How does Jazz Pharmaceuticals compare to Corcept Therapeutics?

Which has stronger valuation & earnings, CORT or JAZZ?

Which has more volatility and risk, CORT or JAZZ?

Do analysts rate CORT or JAZZ?

Does the media refer more to CORT or JAZZ?

Do institutionals and insiders hold more shares of CORT or JAZZ?

Is CORT or JAZZ more profitable?

Summary

How does Jazz Pharmaceuticals compare to Supernus Pharmaceuticals?

Does the media prefer SUPN or JAZZ?

Which has better earnings and valuation, SUPN or JAZZ?

Which has more volatility & risk, SUPN or JAZZ?

Is SUPN or JAZZ more profitable?

Do analysts rate SUPN or JAZZ?

Do institutionals & insiders hold more shares of SUPN or JAZZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JAZZ vs. The Competition

Jazz Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools